| Literature DB >> 35748713 |
Souvik Seal1, Debashis Ghosh1.
Abstract
MOTIVATION: Studying the interaction or co-expression of the proteins or markers in the tumor microenvironment (TME) of cancer subjects can be crucial in the assessment of risks, such as death or recurrence. In the conventional approach, the cells need to be declared positive or negative for a marker based on its intensity. For multiple markers, manual thresholds are required for each marker, which can become cumbersome. The performance of the subsequent analysis relies heavily on this step and thus suffers from subjectivity and lacks robustness.Entities:
Year: 2022 PMID: 35748713 PMCID: PMC9344855 DOI: 10.1093/bioinformatics/btac414
Source DB: PubMed Journal: Bioinformatics ISSN: 1367-4803 Impact factor: 6.931
Fig. 1.Comparison of the workflow of the proposed method with the traditional method. We used segmented cell-level data in this article but the method is applicable on a pixel-level data as well
Estimated coefficient, hazard ratio (HR) and LRT P-value for testing association with 5-year overall survival using different methods in the mIHC lung cancer dataset
| Method | Coefficient (HR) | LRT |
|---|---|---|
|
| −7.26 (0.0007) | 0.0286 |
| Corr | −1.38 (0.2512) | 0.1838 |
| Median-thresholding | −0.48 (0.6189) | 0.0495 |
| Threshold 1 | −0.58 (0.5585) | 0.0575 |
| Threshold 2 | −1.03 (0.3555) | 0.0098 |
Estimated coefficient and LRT P-value for testing association with recurrence and survival for five combinations of the markers from sets (a) and (b) with the lowest P-values, obtained by the proposed method in the MIBI dataset
| Clinical | Marker | Coefficient | LRT |
|---|---|---|---|
| Outcome | Combination |
| |
| Recurrence | HLA-DR, CD45RO | −32.97 | 0.0022 |
| HLA-DR, CD45RO, H3K9ac | −12.48 | 0.0051 | |
| HLA-DR, CD45RO, H3K27me3 | −6.73 | 0.0245 | |
| CD45RO, H3K9ac | −41.53 | 0.0329 | |
| HLA-DR, CD45RO, HLA-Class-1 | −7.20 | 0.0421 | |
| Survival | HLA-Class-1, H3K27me3 | −12.75 | 0.1010 |
| HLA-DR, H3K9ac | −8.27 | 0.1542 | |
| HLA-DR, CD45RO | −8.35 | 0.1583 | |
| HLA-DR, HLA-Class-1 | −29.69 | 0.1630 | |
| HLA-DR, CD45RO, H3K9ac | −0.74 | 0.3158 | |
| Recurrence | PD1, PD-L1 | −9.61e + 03 | 0.0046 |
| PD1, PD-L1, IDO | −5.54e + 02 | 0.0065 | |
| PD1, PD-L1, Lag3, IDO | −4.37e + 02 | 0.0069 | |
| PD-L1, Lag3, IDO | −8.94e + 02 | 0.0084 | |
| PD1, PD-L1, Lag3 | −1.91e + 02 | 0.0090 | |
| Survival | PD-L1, Lag3 | −1.20e + 02 | 0.0103 |
| Lag3, IDO | −1.14e + 02 | 0.0302 | |
| PD-L1, Lag3, IDO | −5.67e + 02 | 0.0449 | |
| PD-L1, IDO | −6.85e + 02 | 0.0490 | |
| PD1, PD-L1, Lag3, IDO | −2.15e + 02 | 0.0586 |
Fig. 2.The figure displays the power of different methods under different simulation scenarios from Section 4.1 with two markers for varying numbers of subjects (N) and cells (). On the x-axis, the fixed effect size β was varied from low to high
Fig. 3.The figure displays the power of different methods under different cases from Section 4.2 with three markers for varying numbers of subjects (N) and cells (). On the x-axis, the fixed effect size β was varied from low to high